Cargando…
Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study
BACKGROUND: Serum antibodies against myelin-oligodendrocyte-glycoprotein (MOG-IgG) are detectable in a proportion of patients with acute or relapsing neuroinflammation. It is unclear, if neuro-axonal damage occurs only in an attack-dependent manner or also progressively. Therefore, this study aimed...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657100/ https://www.ncbi.nlm.nih.gov/pubmed/31345223 http://dx.doi.org/10.1186/s12974-019-1521-5 |
_version_ | 1783438744339087360 |
---|---|
author | Oertel, Frederike C. Outteryck, Olivier Knier, Benjamin Zimmermann, Hanna Borisow, Nadja Bellmann-Strobl, Judith Blaschek, Astrid Jarius, Sven Reindl, Markus Ruprecht, Klemens Meinl, Edgar Hohlfeld, Reinhard Paul, Friedemann Brandt, Alexander U. Kümpfel, Tania Havla, Joachim |
author_facet | Oertel, Frederike C. Outteryck, Olivier Knier, Benjamin Zimmermann, Hanna Borisow, Nadja Bellmann-Strobl, Judith Blaschek, Astrid Jarius, Sven Reindl, Markus Ruprecht, Klemens Meinl, Edgar Hohlfeld, Reinhard Paul, Friedemann Brandt, Alexander U. Kümpfel, Tania Havla, Joachim |
author_sort | Oertel, Frederike C. |
collection | PubMed |
description | BACKGROUND: Serum antibodies against myelin-oligodendrocyte-glycoprotein (MOG-IgG) are detectable in a proportion of patients with acute or relapsing neuroinflammation. It is unclear, if neuro-axonal damage occurs only in an attack-dependent manner or also progressively. Therefore, this study aimed to investigate longitudinally intra-retinal layer changes in eyes without new optic neuritis (ON) in MOG-IgG-seropositive patients. METHODS: We included 38 eyes of 24 patients without ON during follow-up (F/U) [median years (IQR)] 1.9 (1.0–2.2) and 56 eyes of 28 age- and sex-matched healthy controls (HC). The patient group’s eyes included 18 eyes without (Eye(ON-)) and 20 eyes with history of ON (Eye(ON+)). Using spectral domain optical coherence tomography (OCT), we acquired peripapillary retinal nerve fiber layer thickness (pRNFL) and volumes of combined ganglion cell and inner plexiform layer (GCIP), inner nuclear layer (INL), and macular volume (MV). High-contrast visual acuity (VA) was assessed at baseline. RESULTS: At baseline in Eye(ON-), pRNFL (94.3 ± 15.9 μm, p = 0.36), INL (0.26 ± 0.03 mm(3), p = 0.11), and MV (2.34 ± 0.11 mm(3), p = 0.29) were not reduced compared to HC; GCIP showed thinning (0.57 ± 0.07 mm(3); p = 0.008), and VA was reduced (logMAR 0.05 ± 0.15 vs. − 0.09 ± 0.14, p = 0.008) in comparison to HC. Longitudinally, we observed pRNFL thinning in models including all patient eyes (annual reduction − 2.20 ± 4.29 μm vs. − 0.35 ± 1.17 μm, p = 0.009) in comparison to HC. Twelve Eye(ON-) with other than ipsilateral ON attacks ≤ 6 months before baseline showed thicker pRNFL at baseline and more severe pRNFL thinning in comparison to 6 Eye(ON-) without other clinical relapses. CONCLUSIONS: We observed pRNFL thinning in patients with MOG-IgG during F/U, which was not accompanied by progressive GCIP reduction. This effect could be caused by a small number of Eye(ON-) with other than ipsilateral ON attacks within 6 months before baseline. One possible interpretation could be a reduction of the swelling, which could mean that MOG-IgG patients show immune-related swelling in the CNS also outside of an attack’s target area. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-019-1521-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6657100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66571002019-07-31 Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study Oertel, Frederike C. Outteryck, Olivier Knier, Benjamin Zimmermann, Hanna Borisow, Nadja Bellmann-Strobl, Judith Blaschek, Astrid Jarius, Sven Reindl, Markus Ruprecht, Klemens Meinl, Edgar Hohlfeld, Reinhard Paul, Friedemann Brandt, Alexander U. Kümpfel, Tania Havla, Joachim J Neuroinflammation Research BACKGROUND: Serum antibodies against myelin-oligodendrocyte-glycoprotein (MOG-IgG) are detectable in a proportion of patients with acute or relapsing neuroinflammation. It is unclear, if neuro-axonal damage occurs only in an attack-dependent manner or also progressively. Therefore, this study aimed to investigate longitudinally intra-retinal layer changes in eyes without new optic neuritis (ON) in MOG-IgG-seropositive patients. METHODS: We included 38 eyes of 24 patients without ON during follow-up (F/U) [median years (IQR)] 1.9 (1.0–2.2) and 56 eyes of 28 age- and sex-matched healthy controls (HC). The patient group’s eyes included 18 eyes without (Eye(ON-)) and 20 eyes with history of ON (Eye(ON+)). Using spectral domain optical coherence tomography (OCT), we acquired peripapillary retinal nerve fiber layer thickness (pRNFL) and volumes of combined ganglion cell and inner plexiform layer (GCIP), inner nuclear layer (INL), and macular volume (MV). High-contrast visual acuity (VA) was assessed at baseline. RESULTS: At baseline in Eye(ON-), pRNFL (94.3 ± 15.9 μm, p = 0.36), INL (0.26 ± 0.03 mm(3), p = 0.11), and MV (2.34 ± 0.11 mm(3), p = 0.29) were not reduced compared to HC; GCIP showed thinning (0.57 ± 0.07 mm(3); p = 0.008), and VA was reduced (logMAR 0.05 ± 0.15 vs. − 0.09 ± 0.14, p = 0.008) in comparison to HC. Longitudinally, we observed pRNFL thinning in models including all patient eyes (annual reduction − 2.20 ± 4.29 μm vs. − 0.35 ± 1.17 μm, p = 0.009) in comparison to HC. Twelve Eye(ON-) with other than ipsilateral ON attacks ≤ 6 months before baseline showed thicker pRNFL at baseline and more severe pRNFL thinning in comparison to 6 Eye(ON-) without other clinical relapses. CONCLUSIONS: We observed pRNFL thinning in patients with MOG-IgG during F/U, which was not accompanied by progressive GCIP reduction. This effect could be caused by a small number of Eye(ON-) with other than ipsilateral ON attacks within 6 months before baseline. One possible interpretation could be a reduction of the swelling, which could mean that MOG-IgG patients show immune-related swelling in the CNS also outside of an attack’s target area. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-019-1521-5) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-25 /pmc/articles/PMC6657100/ /pubmed/31345223 http://dx.doi.org/10.1186/s12974-019-1521-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Oertel, Frederike C. Outteryck, Olivier Knier, Benjamin Zimmermann, Hanna Borisow, Nadja Bellmann-Strobl, Judith Blaschek, Astrid Jarius, Sven Reindl, Markus Ruprecht, Klemens Meinl, Edgar Hohlfeld, Reinhard Paul, Friedemann Brandt, Alexander U. Kümpfel, Tania Havla, Joachim Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study |
title | Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study |
title_full | Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study |
title_fullStr | Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study |
title_full_unstemmed | Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study |
title_short | Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study |
title_sort | optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657100/ https://www.ncbi.nlm.nih.gov/pubmed/31345223 http://dx.doi.org/10.1186/s12974-019-1521-5 |
work_keys_str_mv | AT oertelfrederikec opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT outteryckolivier opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT knierbenjamin opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT zimmermannhanna opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT borisownadja opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT bellmannstrobljudith opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT blaschekastrid opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT jariussven opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT reindlmarkus opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT ruprechtklemens opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT meinledgar opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT hohlfeldreinhard opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT paulfriedemann opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT brandtalexanderu opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT kumpfeltania opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy AT havlajoachim opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy |